Phase 2 trial of AskBio’s gene therapy assigns its first participants
A Phase 2 clinical trial of AB-1005, AskBio’s gene therapy for Parkinson’s disease, has randomly assigned its first participants to different treatment groups, the company has announced. Called REGENERATE-PD (NCT06285643), the trial is expected to